Evidence map›Paper›PMID 37632309›Full record

ArticleESC heart failure2023

Importance of the 'area under the curve' from serial NT-proBNP measurements during treatment with sacubitril/valsartan.

Reza Mohebi, Yuxi Liu, Javed Butler, G Michael Felker, Jonathan H Ward, Margaret F Prescott, Ileana L Piña, Scott D Solomon, James L Januzzi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Reza MohebiMassachusetts General Hospital, Boston, MA, USA.
Yuxi LiuMassachusetts General Hospital, Boston, MA, USA.
Javed ButlerUniversity of Mississippi Medical Center, Jackson, MS, USA.
G Michael FelkerDuke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA.
Jonathan H WardNovartis Pharmaceuticals, East Hanover, NJ, USA.
Margaret F PrescottNovartis Pharmaceuticals, East Hanover, NJ, USA.
Ileana L PiñaCentral Michigan University, Midland, MI, USA.
Scott D SolomonHarvard Medical School, Boston, MA, USA.
James L JanuzziMassachusetts General Hospital, Boston, MA, USA.

Funding

Barry FellowshipHutter Family ProfessorshipNovartis Pharmaceuticals Corporation
6 · The paper itself

Abstract

aimsSerial assessment of natriuretic peptides is widely utilized in heart failure clinics. Uncertainty exists regarding the value of multiple natriuretic peptide measurements and how they might be best interpreted. METHODS AND

resultsSix hundred thirty-two patients with heart failure with reduced ejection fraction (<40%) and complete biomarker data were enrolled to receive sacubitril/valsartan. Patients underwent periodic study visits during 1-year follow-ups. Echocardiographic data and cardiac biomarkers, including N-terminal pro-B-type natriuretic peptide (NT-proBNP) were collected during study visits. Patients were categorized into three groups based on tertiles of baseline NT-proBNP levels. The area under the curve (AUC) of NT-proBNP measurements across study visits was calculated. Compared with patients with higher AUC (and thus higher concentrations over a longer period of time), those with lower AUC were younger, had a lower prevalence of chronic kidney disease, prior coronary artery bypass graft, atrial fibrillation, and higher body-mass index. A significant interaction existed between baseline NT-proBNP and subsequent AUC for predicting LVEF change across visits (P-value < 0.001): among those with lower baseline NT-proBNP, similar improvements in left ventricular (LV) volumes LV ejection fraction, and LV mass index were observed across subsequent AUC (P-value > 0.1). However, among those with higher baseline NT-proBNP, those with lower subsequent AUC had a greater improvement in cardiac remodelling indices (P-value < 0.05).

conclusionsSerial NT-proBNP monitoring (integrating the totality of measurements as an AUC) during treatment with sacubitril/valsartan informs unique information regarding the future changes in cardiac remodelling indices, especially among those with higher NT-proBNP levels at baseline.

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsBiomarkersBiphenyl CompoundsDrug CombinationsHeart FailureNatriuretic Peptide, BrainPeptide FragmentsStroke VolumeValsartanAgedArea Under CurveEchocardiographyFemaleFollow-Up StudiesHumansAminobutyratesAngiotensin Receptor AntagonistsBiomarkersBiphenyl CompoundsDrug CombinationsNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)sacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanBiomarkerCardiac remodellingNatriuretic peptideSacubitril/valsartan

Identifiers

PMID37632309
PMCPMC10567633

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.